Intellia Therapeutics and Regeneron Pharmaceuticals have completed enrollment for their Phase 3 MAGNITUDE-2 clinical trial of nex-z, a CRISPR-based therapeutic for transthyretin amyloidosis. This milestone signals progress towards a potential one-time treatment for a rare disease, which could significantly impact both companies if successful.
Intellia Therapeutics and Regeneron Pharmaceuticals announced the completion of patient enrollment in their Phase 3 MAGNITUDE-2 clinical trial for nex-z. This is a significant operational milestone for the development of nex-z, an investigational in vivo CRISPR-based therapeutic for transthyretin amyloidosis (ATTRv-PN). The completion of enrollment de-risks the trial timeline and moves the companies closer to potential data readouts and regulatory submissions. For Intellia, this represents progress on a key pipeline asset, while for Regeneron, it strengthens their collaboration and potential future revenue streams. Short-term, this could generate positive sentiment for both stocks, while long-term implications depend on the trial's success, offering a significant opportunity for traders if the drug proves effective in treating this rare, fatal disease.